Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study.

Hermsen BB, Olivier RI, Verheijen RH, van Beurden M, de Hullu JA, Massuger LF, Burger CW, Brekelmans CT, Mourits MJ, de Bock GH, Gaarenstroom KN, van Boven HH, Mooij TM, Rookus MA.

Br J Cancer. 2007 May 7;96(9):1335-42. Epub 2007 Apr 10.

2.

Clinicopathologic characteristics and survival in BRCA1- and BRCA2-related adnexal cancer: are they different?

Reitsma W, de Bock GH, Oosterwijk JC, ten Hoor KA, Hollema H, Mourits MJ.

Int J Gynecol Cancer. 2012 May;22(4):579-85. doi: 10.1097/IGC.0b013e31823d1b5c.

PMID:
22274543
3.

Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.

van der Kolk DM, de Bock GH, Leegte BK, Schaapveld M, Mourits MJ, de Vries J, van der Hout AH, Oosterwijk JC.

Breast Cancer Res Treat. 2010 Dec;124(3):643-51. doi: 10.1007/s10549-010-0805-3. Epub 2010 Mar 4.

PMID:
20204502
4.

Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.

Fakkert IE, Jansen L, Meijer K, Kok T, Oosterwijk JC, Mourits MJ, de Bock GH.

Breast Cancer Res Treat. 2011 Aug;129(1):157-64. doi: 10.1007/s10549-011-1423-4. Epub 2011 Mar 4.

PMID:
21373873
5.

Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K.

Clin Cancer Res. 2002 Dec;8(12):3776-81.

6.

Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study.

Gaarenstroom KN, van der Hiel B, Tollenaar RA, Vink GR, Jansen FW, van Asperen CJ, Kenter GG.

Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:54-9.

PMID:
16515568
7.

Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.

Saadatmand S, Vos JR, Hooning MJ, Oosterwijk JC, Koppert LB, de Bock GH, Ausems MG, van Asperen CJ, Aalfs CM, Gómez Garcia EB, Meijers-Heijboer H, Hoogerbrugge N, Piek M, Seynaeve C, Verhoef C, Rookus M, Tilanus-Linthorst MM; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON).

Int J Cancer. 2014 Dec 15;135(12):2940-9. doi: 10.1002/ijc.28941. Epub 2014 May 20.

8.

Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.

Domchek SM, Gaudet MM, Stopfer JE, Fleischaut MH, Powers J, Kauff N, Offit K, Nathanson KL, Robson M.

Breast Cancer Res Treat. 2010 Jan;119(2):409-14. doi: 10.1007/s10549-009-0611-y.

PMID:
19885732
9.

Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.

Metcalfe K, Lubinski J, Lynch HT, Ghadirian P, Foulkes WD, Kim-Sing C, Neuhausen S, Tung N, Rosen B, Gronwald J, Ainsworth P, Sweet K, Eisen A, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

J Natl Cancer Inst. 2010 Dec 15;102(24):1874-8. doi: 10.1093/jnci/djq443. Epub 2010 Nov 23.

PMID:
21098759
10.

Complete BRCA mutation screening in breast and ovarian cancer predisposition families from a North-Eastern Romanian population.

Negura L, Uhrhammer N, Negura A, Artenie V, Carasevici E, Bignon YJ.

Fam Cancer. 2010 Dec;9(4):519-23. doi: 10.1007/s10689-010-9361-6.

PMID:
20567915
11.

Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer.

Kaas R, Verhoef S, Wesseling J, Rookus MA, Oldenburg HS, Peeters MJ, Rutgers EJ.

Ann Surg. 2010 Mar;251(3):488-92. doi: 10.1097/SLA.0b013e3181c3c36d.

PMID:
20134318
12.

Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.

Metcalfe KA, Finch A, Poll A, Horsman D, Kim-Sing C, Scott J, Royer R, Sun P, Narod SA.

Br J Cancer. 2009 Jan 27;100(2):421-5. doi: 10.1038/sj.bjc.6604830. Epub 2008 Dec 16.

13.

Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers.

Evans DG, Gaarenstroom KN, Stirling D, Shenton A, Maehle L, Dørum A, Steel M, Lalloo F, Apold J, Porteous ME, Vasen HF, van Asperen CJ, Moller P.

J Med Genet. 2009 Sep;46(9):593-7. doi: 10.1136/jmg.2008.058248. Epub 2008 Apr 15.

PMID:
18413372
14.

Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing.

Botkin JR, Smith KR, Croyle RT, Baty BJ, Wylie JE, Dutson D, Chan A, Hamann HA, Lerman C, McDonald J, Venne V, Ward JH, Lyon E.

Am J Med Genet A. 2003 Apr 30;118A(3):201-9.

PMID:
12673648
15.

Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families.

Evans DG, Young K, Bulman M, Shenton A, Wallace A, Lalloo F.

Clin Genet. 2008 Apr;73(4):338-45. doi: 10.1111/j.1399-0004.2008.00974.x. Epub 2008 Feb 26.

PMID:
18312450
16.

Pathology of ovarian cancers in BRCA1 and BRCA2 carriers.

Lakhani SR, Manek S, Penault-Llorca F, Flanagan A, Arnout L, Merrett S, McGuffog L, Steele D, Devilee P, Klijn JG, Meijers-Heijboer H, Radice P, Pilotti S, Nevanlinna H, Butzow R, Sobol H, Jacquemier J, Lyonet DS, Neuhausen SL, Weber B, Wagner T, Winqvist R, Bignon YJ, Monti F, Schmitt F, Lenoir G, Seitz S, Hamman U, Pharoah P, Lane G, Ponder B, Bishop DT, Easton DF.

Clin Cancer Res. 2004 Apr 1;10(7):2473-81.

17.
18.

The carrier clinic: an evaluation of a novel clinic dedicated to the follow-up of BRCA1 and BRCA2 carriers--implications for oncogenetics practice.

Bancroft EK, Locke I, Ardern-Jones A, D'Mello L, McReynolds K, Lennard F, Barbachano Y, Barwell J, Walker L, Mitchell G, Dorkins H, Cummings C, Paterson J, Kote-Jarai Z, Mitra A, Jhavar S, Thomas S, Houlston R, Shanley S, Eeles RA.

J Med Genet. 2010 Jul;47(7):486-91. doi: 10.1136/jmg.2009.072728. Epub 2010 May 14.

PMID:
20472659
19.

Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic.

Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB, van Geel AN, Tilanus-Linthorst MM, Bartels CC, Tan M, Meijers-Heijboer HE, Klijn JG, Seynaeve C.

Ann Surg Oncol. 2007 Dec;14(12):3335-44. Epub 2007 May 31.

20.

BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study.

Bjørge T, Lie AK, Hovig E, Gislefoss RE, Hansen S, Jellum E, Langseth H, Nustad K, Tropé CG, Dørum A.

Br J Cancer. 2004 Nov 15;91(10):1829-34.

Supplemental Content

Support Center